Overall Ranking

Traffic Ranking

Investment Ranking

Fallers Ranking

Ranking by Popular rankings

All rankings in Popular rankings

Data-Driven policy: How the Province of Groningen uses RankmyAI to track AI growth

Data-Driven policy: How the Province of Groningen uses RankmyAI to track AI growth

Dante Tenbergen, Policy Officer for the Digital Economy at the Province of Groningen, uses data to prepare the region for a future beyond large-scale natural gas extraction and its consequences. In this conversation, he explains his work and how the collaboration with RankmyAI helps him understand the rapidly developing IT and AI sector in Groningen.

Beyond GPUs: The New Compute Stack Powering AI’s Next Decade

Beyond GPUs: The New Compute Stack Powering AI’s Next Decade

If 2023–2024 crowned foundation models, 2025 belongs to the machines they run on. At Web Summit 2025, hardware had gravitational pull. RankMyAI was there to track these developments firsthand. The message was blunt: AI advantage starts with the right chips, in the right places.

GT Apeiron Therapeutics

overall

out of 62,432

+809

traffic

out of 62,432

+271

investment

out of 62,432

-94

review

Not Available

These rankings are based on data from March 2026

Company

GT Apeiron Therapeutics

Years in business

7

Number of employees

11-50 employees

Country

United States

Apeiron Therapeutics is a clinical-stage biopharmaceutical company developing biomarker-driven, AI-enabled small molecule therapies for cancer. The company leverages structure-based, AI-driven drug design to build a pipeline of targeted treatments, aiming for best-in-class and first-in-class oncology candidates that address unmet medical needs.

API Availability

Unknown

Pricing

unknown

Use

drug discovery & development

Position of GT Apeiron Therapeutics on sub rankings

March 2026

AI drug discovery & development - Overall

10 out of 62

United States - Overall

2,131 out of 17,204

AI drug discovery & development - Overall

10 out of 62

United States - Overall

2,131 out of 17,204

Industries

health & sports

research & development

Company

GT Apeiron Therapeutics

Years in business

7

Number of employees

11-50 employees

Country

United States

Help us improve this profile

Insights

Sune Selsbæk-Reitz on promptism, fluent machines, and why AI makes it easier to stop thinking too soon

Sune Selsbæk-Reitz on promptism, fluent machines, and why AI makes it easier to stop thinking too soon

An interview with Sune Selsbæk-Reitz on his new book Promptism and why the real risk of AI is not in the technology itself, but in how we use it. He explains how fluent systems influence thinking, why knowledge matters more than ever, and what professionals should do to stay in control.

9 Fresh AI Tools: From scam checks to startup plans

9 Fresh AI Tools: From scam checks to startup plans

This month brought another strong batch of new submissions to RankmyAI. Thanks again to the builders and users who keep pointing us to tools we should track.